Get the Stockscreener App
60.61
3.27%
1.92
After Hours:
60.61
Oruka Therapeutics Inc stock is traded at $60.61, with a volume of 1.10M.
It is up +3.27% in the last 24 hours and down -13.02% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$58.69
Open:
$58.97
24h Volume:
1.10M
Relative Volume:
0.81
Market Cap:
$3.66B
Revenue:
-
Net Income/Loss:
$-105.43M
P/E Ratio:
-26.14
EPS:
-2.3183
Net Cash Flow:
$-88.42M
1W Performance:
-2.13%
1M Performance:
-13.02%
6M Performance:
+106.93%
1Y Performance:
+441.64%
1-Day Range:
$57.98
$61.15
1-Week Range:
$54.99
$62.17
52-Week Range:
$10.63
$91.00
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
60.61 | 3.54B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Oruka Therapeutics(ORKA.US) Director Sells US$6.19 Million in Common Stock - Moomoo
Oruka Therapeutics director Carl Dambkowski sells $6.19m in stock - Investing.com UK
Oruka Therapeutics director Carl Dambkowski sells $6.19m in stock By Investing.com - Investing.com Canada
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors - AOL.com
Oruka Therapeutics (ORKA) director sells 105,000 shares, exercises 62,260 options - Stock Titan
105,000 common shares proposed for sale by ORKA (NASDAQ: ORKA) - Stock Titan
Oruka Therapeutics SVP Arjun Agarwal sells $607,806 in stock By Investing.com - Investing.com Australia
Oruka Therapeutics (ORKA) finance SVP sells 10,290 shares under plan - Stock Titan
Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co. - Moomoo
ORKA (NASDAQ: ORKA) insiders list 22,206 common shares for sale - Stock Titan
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
ORKA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus
How Investors May Respond To Oruka Therapeutics (ORKA) Psoriasis Data And Upsized US$700 Million Offering - Sahm
Oruka Therapeutics CMO Joana Goncalves sells $432,935 in stock - Investing.com UK
Oruka Therapeutics CMO Joana Goncalves sells $432,935 in stock By Investing.com - Investing.com Canada
Oruka Therapeutics (ORKA) CMO sells 7,000 shares after option exercises under 10b5-1 plan - Stock Titan
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Viking shows 2.67M-share stake in Oruka Therapeutics (ORKA) - Stock Titan
Oruka Therapeutics (ORKA) Valuation Check After Psoriasis Trial Progress Partnerships And Fresh Funding - Yahoo Finance
ORKA's Outperform Rating Reiterated At Wedbush, Eyes Key Psoriasis Data In 2H 2026 - RTTNews
Oruka Therapeutics (ORKA) price target increased by 50.51% to 138.41 - MSN
A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $151 to $180 - Moomoo
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Oruka Reports 63.5% PASI 100 Rate for ORKA-001 at Week 16 in Psoriasis - The Clinical Trial Vanguard
ORKA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Flash (ORKA) Oruka Therapeutics Posts Q1 Per Share Loss $0.48, vs. FactSet Est of Loss $0.55 - marketscreener.com
Earnings Flash (ORKA) Oruka Therapeutics Posts Q1 Per Share Loss $0.48, Vs. FactSet Est of Loss $0.55 - Moomoo
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally - Yahoo Finance
Press Release: Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Oruka Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Oruka Therapeutics (ORKA) ramps R&D and raises over $700M in new equity - Stock Titan
ETFs Investing in Oruka Therapeutics, Inc. Stocks - TradingView
Assessing Oruka Therapeutics (ORKA) Valuation After Equity Raise Collaboration Deal And Trial Updates - Sahm
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE - PR Newswire
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? - The Motley Fool
Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA) - Insider Monkey
ORKA stock is soaring after psoriasis trial results — here's why BTIG hiked its price target by 94% - MSN
Why Oruka Therapeutics (ORKA) Is Down 6.3% After $700 Million Follow-On Amid Psoriasis Breakthrough - Yahoo Finance
Oruka Therapeutics shares jump on strong psoriasis trial results - MSN
5 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
Psoriasis Data, Halozyme Pact and Equity Raise Might Change The Case For Investing In Oruka Therapeutics (ORKA) - Sahm
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Biotech's 121.89% Potential Upside Captivates Investors - DirectorsTalk Interviews
MSN Money - MSN
Halozyme (HALO) Enters Global Partnership with Oruka Therapeutics - GuruFocus
Oruka Therapeutics (ORKA) slides 8.2% as investors digest recent $700M equity raise - Quiver Quantitative
Halozyme and Oruka sign agreement for Hypercon technology - Yahoo Finance
Halozyme Agrees to License Hypercon Technology to Oruka to Develop Psoriasis Treatment - Contract Pharma
Halozyme licenses Hypercon technology to Oruka for psoriasis drug By Investing.com - Investing.com South Africa
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):